anti tirzepatide antibody reaction Pharmacogenomics of Tirzepatide: Genomic Insights into Dual GIP/GLP-1 Agonist Response in Type 2 Diabetes and Atherosclerosis tirzepatide antibodies anti Technological advancements

Lower Blood Pressure Semaglutide has been shown to reduce systolic blood pressure, which is essential for cardiovascular health

BY ELLE NKOSI Jun 14 5 min read Updated: Jun 16 As Ozempic and other GLP-1 medications continue to reshape the weight-loss landscape, a few questions are emerging among clinicians, researchers, and patients alike

For patients without established atherosclerotic CV disease (ASCVD) or chronic kidney disease (CKD) and for whom there is a compelling need to minimize weight gain or promote weight loss, the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) guidelines recommend GLP-1RA and sodium-glucose co-transporter-2 inhibitor (SGLT2i) drugs as the preferred second-line treatment option for patients with inadequate glycemic control despite use of metformin [1, 9]

Manufactured in a GMP-compliant, FSSAI-certified facility for private label and international bulk exports